title: Selective inhibition of amine oxidases differently potentiate the hypophagic effect of benzylamine in mice.
abstract: In mice deprived of food for 12 h, the i.c.v. or i.p. administration of benzylamine, a substrate common to both monoamine oxidase B and semicarbazide-sensitive benzylamine oxidases, dose-dependently inhibited feeding. This effect was significantly potentiated by selective monoamine oxidase A and B inhibition, suggesting that central monoamines, known to be substrates of these enzymes may be released. The i.p. administration of semicarbazide-sensitive benzylamine oxidase inhibitors, B24 (3,5-ethoxy-4-aminomethylpyridine) and MDL 72274 ((E)-2-phenyl-3-chloroallylamine) strongly potentiated the effect of i.p. but not i.c.v.-administered benzylamine. The hypophagic effect of benzylamine was evaluated following i.c.v. administration, in comparison with the effect of the sympathomimetic compound amphetamine or the K(+) channel blocker tetraethylammonium, as reference compounds. Our results make it possible to define benzylamine as a centrally acting hypophagic compound devoid of amphetamine-like motor stimulatory effects and point to a role of B24 and MDL 72274 as specific peripheral enhancers of the pharmacological effects of benzylamine.
authors.affiliation: Department of Preclinical and Clinical Pharmacology, University of Florence, Viale Pieraccini 6, 50134 Florence, Italy.
authors.forename: G
authors.initials: G
authors.lastname: Banchelli
authors.forename: C
authors.initials: C
authors.lastname: Ghelardini
authors.forename: L
authors.initials: L
authors.lastname: Raimondi
authors.forename: N
authors.initials: N
authors.lastname: Galeotti
authors.forename: R
authors.initials: R
authors.lastname: Pirisino
mesh_terms: D000498:Allyl Compounds / Q000494:pharmacology; D000661:Amphetamine / Q000494:pharmacology; D000818:Animals; D001596:Benzylamines / Q000494:pharmacology*; D003010:Clorgyline / Q000494:pharmacology; D015259:Dopamine Agents / Q000494:pharmacology; D004357:Drug Synergism; D005247:Feeding Behavior / Q000187:drug effects*; D008297:Male; D051379:Mice; D008995:Monoamine Oxidase / Q000378:metabolism*; D008996:Monoamine Oxidase Inhibitors / Q000494:pharmacology*; D009043:Motor Activity / Q000187:drug effects; D010879:Piperazines / Q000494:pharmacology; D011437:Propylamines / Q000494:pharmacology; D011725:Pyridines / Q000494:pharmacology; D012642:Selegiline / Q000494:pharmacology; D012702:Serotonin Antagonists / Q000494:pharmacology; D013379:Substrate Specificity; D019789:Tetraethylammonium / Q000494:pharmacology
chemical_list: C094718:3,5-diethoxy-4-aminomethylpyridine; D000498:Allyl Compounds; D001596:Benzylamines; D015259:Dopamine Agents; C090015:MDL 72274A; D008996:Monoamine Oxidase Inhibitors; D010879:Piperazines; D011437:Propylamines; D011725:Pyridines; D012702:Serotonin Antagonists; D012642:Selegiline; D019789:Tetraethylammonium; C090413:N-(2-(4-(2-methoxyphenyl)-1-piperazinyl)ethyl)-N-(2-pyridinyl)cyclohexanecarboxamide; C030796:benzylamine; D000661:Amphetamine; D008995:Monoamine Oxidase; D003010:Clorgyline